Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5913639 | 0.98 | ALDH1A1 (0.48) | ALDH1A1SLC6A4HTR2ACASP1PRKCI | |
| SCHEMBL2174004 | 0.85 | ALDH1A1 (0.48) | ALDH1A1SLC6A4HTR2ACASP1PRKCI | |
| SCHEMBL1708813 | 0.84 | SLC6A4 (0.50) | ALDH1A1SLC6A4HTR2ACASP1PRKCI | |
| SCHEMBL30402664 | 0.81 | SLC6A4 (0.64) | ALDH1A1SLC6A4HTR2APRKCICYP3A4 | |
| SCHEMBL4525352 | 0.81 | SLC6A4 (0.47) | ALDH1A1SLC6A4HTR2APRKCIACHE | |
| SCHEMBL4532794 | 0.81 | SLC6A4 (0.47) | ALDH1A1SLC6A4HTR2APRKCICYP3A4 | |
| SCHEMBL3338265 | 0.81 | PRKCI (0.69) | ALDH1A1SLC6A4HTR2ACASP1PRKCI | |
| SCHEMBL1664066 | 0.81 | SLC6A4 (0.64) | ALDH1A1SLC6A4HTR2APRKCICYP3A4 | |
| SCHEMBL29834174 | 0.81 | PRKCI (0.69) | ALDH1A1SLC6A4HTR2ACASP1PRKCI | |
| SCHEMBL10324596 | 0.81 | SLC6A4 (0.47) | ALDH1A1SLC6A4HTR2APRKCITSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| EP-3256452-A1 | INHIBITORS OF NECROPTOSIS | Catalyst Therapeutics Pty Ltd. (AU) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016127213-A1 | INHIBITORS OF NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016127213-A1 | INHIBITORS OF NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2016-08-18 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1068178-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999044987-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885SLC6A4 478/4885HTR2A 2286/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885SLC6A4 1676/4885HTR2A 1721/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | ALDH1A1 4651/4885SLC6A4 4872/4885HTR2A 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.